CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Open-market sale Chief Executive Officer sold 3,091 shares at $0.76 ($2,348)
- 4 Open-market sale General Counsel sold 2,323 shares at $0.73 ($1,707)
- 4 Open-market sale Chief Executive Officer sold 10,847 shares at $0.73 ($7,970)
- 4 Open-market sale Sinha Vikas sold 5,251 shares at $0.73 ($3,858)
- 4 Open-market sale Chief Accounting Officer sold 1,692 shares at $0.73 ($1,243)
- 4 Open-market sale Chief Accounting Officer sold 960 shares at an average $0.74 ($715)
- 4 Open-market sale Chief Executive Officer sold 9,731 shares at $0.75 ($7,299)
- 4 Open-market sale Sinha Vikas sold 3,400 shares at an average $0.74 ($2,530)
- 4 Open-market sale General Counsel sold 1,391 shares at an average $0.74 ($1,035)
- 4 Open-market sale General Counsel sold 379 shares at $0.72 ($273)
- 4 Open-market sale Sinha Vikas sold 939 shares at $0.72 ($676)
- 4 Open-market sale Chief Accounting Officer sold 304 shares at $0.72 ($219)
- 4 Open-market sale Chief Executive Officer sold 1,489 shares at $0.72 ($1,072)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
Page 5 of 19 · 363 filings